Search

Your search keyword '"Rivero Yeverino D"' showing total 45 results

Search Constraints

Start Over You searched for: Author "Rivero Yeverino D" Remove constraint Author: "Rivero Yeverino D"
45 results on '"Rivero Yeverino D"'

Search Results

1. Changes in Skin Test Aeroallergen Sensitization in Mexico Over the Past 14 Years and According to Climate

2. Adherence to inhaled corticosteroids and long-acting β2-agonists in asthma: A MASK-air study

3. Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology

5. Correlation between work impairment, scores of rhinitis severity and asthma using the MASK-air ® App

6. Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma

7. MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence

8. Is diet partly responsible for differences in COVID-19 death rates between and within countries?

9. Childhood asthma outcomes during the COVID-19 pandemic:findings from the PeARL multinational cohort

10. Childhood asthma outcomes during the COVID-19 pandemic: Findings from the PeARL multi-national cohort

11. ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma

12. Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma

13. ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence

14. Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018) : Change management in allergic rhinitis and asthma multimorbidity using mobile technology

15. Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma.

16. MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence

17. Mask 2017: Aria Digitally-Enabled, Integrated, Person-Centred Care For Rhinitis And Asthma Multimorbidity Using Real-World-Evidence

18. MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence

19. MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence

20. MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence.

21. Caso clínico: síndrome de DRESS por hidroxicloroquina.

22. Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology

23. Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology

24. Nrf2-interacting nutrients and COVID-19: time for research to develop adaptation strategies

25. [Therapeutic effect of vitamin D supplementation in mexican patients with allergic rhinitis].

26. Relevance of individual bronchial symptoms for asthma diagnosis and control in patients with rhinitis: A MASK-air study.

27. Recommendations for asthma monitoring in children: A PeARL document endorsed by APAPARI, EAACI, INTERASMA, REG, and WAO.

28. [Diagnóstico de alergia inmediata para penicilina: estudio piloto].

29. [Pruebas diagnósticas in vivo en alergia inmediata a penicilina: estudio piloto].

30. Aeroallergen immunotherapy associated with reduced risk of severe COVID-19 in 1095 allergic patients.

31. [Vitamin D and respiratory allergy: state of the art].

32. Childhood asthma outcomes during the COVID-19 pandemic: Findings from the PeARL multi-national cohort.

33. ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice.

34. [The effectiveness and safety of subcutaneous immunotherapy for inhalable allergens in patients with respiratory allergies after one year of treatment].

35. Compromising between European and US allergen immunotherapy schools: Discussions from GUIMIT, the Mexican immunotherapy guidelines.

36. [Executive Summary of ARIA 2019: Integrated care pathways for allergic rhinitis in Argentina, Spain and Mexico].

37. [The effectiveness and safety of subcutaneous immunotherapy for inhalable allergens in patients with respiratory allergies].

38. [MASK (Mobile Airways Sentinel Network), a mobile App with ARIA's comprehensive solution in Spanish-speaking countries].

39. Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma.

40. [Sensitivity and specificity of the modified epicutaneous patch test in the diagnosis of respiratory allergy to Dermatophagoides pteronyssinus].

41. Spirometry: basic concepts.

42. [GUIMIT 2019, Mexican Guideline on Immunotherapy. Guideline on the diagnosis of IgE-mediated allergic disease and immunotherapy following the ADAPTE approach].

43. [MASK (Mobile Airways Sentinel Network). ARIA's comprehensive solution for mobile app for the multimorbidity of allergic rhinitis and asthma].

44. [Frequency of skin reactivity to food allergens in allergic patients].

45. [Skin reactivity frequency to aeroallergens in patients with clinical symptoms of allergic disease].

Catalog

Books, media, physical & digital resources